Internal Medicine

Ali Naderi, MD

Portrait

Associate Professor of Internal Medicine  - Hematology, Oncology and Blood and Marrow Transplantation

Contact Information

Office: 3202 MERF
Iowa City, IA 52242
Office Phone: 319-384-0067

Email: ali-naderi@uiowa.edu
Web: http://www.medicine.uiowa.edu/dept_primary_apr.aspx?appointment=Internal Medicine&id=nader

Education

MD, Shahid-Beheshti Univeristy of Medical Sciences

Residency, University of Maryland, Harbor Hospital Center, MD
Residency, Wayne State University, Detroit Medical Center, MI
Fellowship, Mayo Graduate School of Medicine, Rochester, MN
Fellowship, Research, University of Cambridge, UK

Licensure and Certifications

Full Registration, General Medical Council, UK
Specialist Registration in Medical Oncology, The Medical Royal Colleges, UK
Certificate of Advanced Standing, Australian Medical Council
Fellow of the American College of Physicians
Iowa Permanent Medical License
Diplomate in Medical Oncology, The American Board of Internal Medicine

Research Summary

I am a medical oncologist and physician-scientist with a special interest in the management of breast cancer. My research is focused on the identification of novel signaling pathways with therapeutic implications in breast cancer and my ultimate goal is the application of our laboratory findings to patient care. I currently have two main research projects in my group:

  1. Estrogen Receptor (ER)-negative Breast Cancer: We are investigating novel signaling pathways in ER-negative breast cancer. In particular we are interested in a subtype of ER-negative breast cancer that is characterized by the overexpression of androgen receptor (AR) and other steroid-response genes (Molecular Apocrine subtype). In this respect, we have identified a number of biologically significant feedback loops between the ErbB2-ERK signaling pathway and some of the key genes that characterize this subtype of breast cancer such as AR, FOXA1, and Prolactin-Induced Protein (PIP). Importantly, some of our findings have potential therapeutic implications and we are exploring the translational aspects of our projects by conducting investigator-initiated trials in patients with ER-negative breast cancer.
  2. BEX2 Pathway in Breast Cancer: We have identified BEX2 as a novel breast cancer gene that promotes survival and growth of breast cancer cells. BEX2 is overexpressed in about half of breast tumors and interacts with some of the key signaling pathways involved in breast tumorigenesis such as c-Jun/JNK, Protein Phosphatase 2A (PP2A), and NF-κB. We are currently characterizing the biochemical and functional aspects of the BEX2 pathway in breast cancer.

Date Last Modified: 06/07/2014 - 21:56:23